SILVER SPRING, Md. — The Food and Drug Administration has approved Exelixis’ Cabometyx (cabozantinib) tablets, the company announced this week. Cabometyx is indicated to treat patients with advanced renal cell carcinoma who have previously received anti-angiogenic treatment.
The new indication for Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) will allow it to be used for patients with genotype 1b chronic hepatitis C and compensated cirrhosis.
The legislation, advocated by both retail pharmacy and the pharma industry, would advance collaboration among health and enforcement authorities to achieve drug abuse solutions that maintain patients’ legitimate access to medications.
The letter points out that copay increases place financial burdens on TRICARE beneficiaries and restrict patient access. In addition, restricting patient access could adversely impact medication compliance and actually increase health costs.